Spatial transcriptomic and proteomic insight into Trop-2, HER2, and AR expression: A pathway to tailored therapies in triple-negative breast cancer. This is an ASCO Meeting Abstract from the 2024 ASCO ...
First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback